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Oncogenic gene expression and epigenetic
remodeling of cis-regulatory elements in ASXL1mutant chronic myelomonocytic leukemia
Moritz Binder 1,2, Ryan M. Carr 1, Terra L. Lasho1, Christy M. Finke1, Abhishek A. Mangaonkar 1,
Christopher L. Pin 3, Kurt R. Berger3, Amelia Mazzone 2,4, Sandeep Potluri5, Tamas Ordog 2,
Keith D. Robertson2, David L. Marks6, Martin E. Fernandez-Zapico6, Alexandre Gaspar-Maia 2,4 ✉ &
Mrinal M. Patnaik 1,2 ✉

Myeloid neoplasms are clonal hematopoietic stem cell disorders driven by the sequential
acquisition of recurrent genetic lesions. Truncating mutations in the chromatin remodeler
ASXL1 (ASXL1MT) are associated with a high-risk disease phenotype with increased proliferation, epigenetic therapeutic resistance, and poor survival outcomes. We performed a
multi-omics interrogation to deﬁne gene expression and chromatin remodeling associated
with ASXL1MT in chronic myelomonocytic leukemia (CMML). ASXL1MT are associated with a
loss of repressive histone methylation and increase in permissive histone methylation and
acetylation in promoter regions. ASXL1MT are further associated with de novo accessibility of
distal enhancers binding ETS transcription factors, targeting important leukemogenic driver
genes. Chromatin remodeling of promoters and enhancers is strongly associated with gene
expression and heterogenous among overexpressed genes. These results provide a comprehensive map of the transcriptome and chromatin landscape of ASXL1MT CMML, forming
an important framework for the development of novel therapeutic strategies targeting
oncogenic cis interactions.
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hronic myeloid neoplasms are malignant clonal hematopoietic stem cell disorders driven by recurrent genetic
events, with an inherent risk of transformation to acute
myeloid leukemia (AML)1,2. Within myeloid neoplasms, chronic
myelomonocytic leukemia (CMML) represents an attractive disease model since it is characterized by both myelodysplastic and
myeloproliferative features, while retaining a relatively simple
clonal composition3. CMML shares the typical repertoire of
genetic driver lesions with other myeloid neoplasms and is particularly enriched in truncating mutations involving ASXL1
(prevalence ~40%)3. The presence of truncating ASXL1 mutations
in CMML is associated with proliferative disease features, resistance to epigenetic therapies, and adverse outcomes4–6. Due to
their independent prognostic signiﬁcance, ASXL1 mutations have
been incorporated in all three contemporary molecularly integrated CMML-speciﬁc prognostic models5,7,8. Given the paucity
of effective therapies for CMML, delineating the molecular
mechanisms of ASXL1-mutant CMML (ASXL1MT) is of particular interest from a therapeutic standpoint.
The sum of evidence from mechanistic studies suggests that
ASXL1 has a complex interactome, that truncating ASXL1
mutations promote leukemogenesis by transcriptional upregulation of leukemogenic drivers including posterior HOXA
genes, and that these mutations recruit several effectors to alter
the epigenome through histone modiﬁcations, increases in
chromatin accessibility, and remodeling of enhancers9–14. However, to our knowledge, no studies have been able to extensively
query the epigenome in primary patient samples. Given the
complexity of human transcriptional regulation in vivo and the
multitude of potential epigenetic mechanisms cooperating to
regulate transcriptional activity, questions remain about the
interplay of regulatory mechanisms in patients with CMML. To
elucidate this interplay, we interrogated the genome, transcriptome, and epigenome of patients with ASXL1-wildtype
(ASXL1WT) and ASXL1MT CMML. In this work, we integrated
somatic mutations, transcription, (hydroxy)methylation, histone
modiﬁcations, and chromatin accessibility to reveal the complexity of the epigenetic landscape, the simultaneous presence of
multiple regulatory mechanisms affecting drivers of leukemogenesis, and remodeling of the enhancer landscape as an
important driver of intratumoral heterogeneity. These insights
into the epigenetic landscape of ASXL1MT CMML generated
from primary patient samples are of considerable interest for the
development of novel targeted therapeutic strategies for patients
with ASXL1MT CMML.
Results
To survey the epigenetic landscape of human CMML, we interrogated mutational spectrum, transcription, DNA methylation,
histone modiﬁcations, and chromatin accessibility in ASXL1MT
(n = 8) and ASXL1WT (n = 8) CMML (Fig. 1a). The clinical
characteristics of the 16 patients with WHO-deﬁned CMML
included in this study are shown in Table 1 and Supplementary
Data 2. All mutations in ASXL1 resulted in a frameshift and were
predicted to lead to a truncation of the protein’s plant homeodomain (Fig. 1b). The spectrum of co-mutations was consistent
with previous observations and included spliceosome components, chromatin regulators, modulators of DNA methylation,
and cell signaling molecules (Fig. 1c). Abnormal karyotypes were
observed in the same number of patients and the burden of comutations was similar between the two groups (median number
per group 3 versus 3, p = 0.508). This included several modulators of DNA methylation including TET2, DNMT3A, and
IDH2 (median number per group 1 versus 1, p = 0.699). As
previously reported, G646W (c.1934dup) was the most prevalent
2

ASXL1 mutation and the observed variant allele frequencies of all
ASXL1 mutations were consistent with heterozygosity15,16. The
presence of truncating ASXL1 mutations was associated with
increased all-cause mortality in the larger patient population seen
at our institution (n = 375) from which the 16 patients is this
study were sampled (Fig. 1d, Supplementary Fig. 1a, b). For
additional information on patient, sample, and cell selection,
please refer to Methods and Supplementary Fig. 1c.
Truncating ASXL1 mutations are associated with transcriptional up-regulation of genes involved in cell cycle progression
and DNA replication. To deﬁne the gene expression proﬁle
associated with truncating ASXL1 mutations, we performed differential gene expression analysis (829 differentially expressed
genes, FDR < 0.050, Fig. 2a, Supplementary Data 3, Supplementary Fig. 2a–c). There was a predominant up-regulation of transcriptional activity (707 genes) among ASXL1MT patients. Of the
707 up-regulated genes in ASXL1MT CMML, 217 were considered
therapeutic targets (Fig. 2a, Supplementary Data 4)17. Unsupervised hierarchical clustering separated ASXL1MT from
ASXL1WT patients (Fig. 2b). Unlike previously reported, we did
observe heterogeneous gene expression proﬁles among the nonG646W ASXL1 mutations16. The two ASXL1MT patients with the
most distally truncating mutations (Q695N and T957H) showed
gene expression proﬁles intermediate between G646W and
ASXL1WT patients (Fig. 2b). We had a priori classiﬁed the
samples based on the genotype (ASXL1MT versus ASXL1WT).
Both samples in question clustered with the other ASXL1MT
samples with regards to their epigenetic features despite the
apparent differences in their gene expression proﬁles (Supplementary Fig. 2d). We therefore maintained our a priori sample
classiﬁcation based on the genotype (ASXL1MT versus ASXL1WT)
for all subsequent analyses. Functional annotation of the differentially expressed genes revealed several affected cellular processes including up-regulation of cell division (Supplementary
Fig. 2e) and down-regulation of MHC class I dependent antigen
presentation (Fig. 2c). Pathway analysis demonstrated an overrepresentation of genes involved in cell cycle (e.g. CDK1, CCNA2,
CCNB2), DNA replication and repair (e.g. MCM10, CDC6,
CDC45), gene expression (e.g. CHEK1, RRM2, BRCA1), signal
transduction (e.g. HLA-A, VCAM1, HLA-DQB1), and antigen
presentation (e.g. CTSE, HLA-A, HLA-DQB1) pathways (Supplementary Fig. 2f, Supplementary Data 5, 6).
Truncating ASXL1 mutations are associated with permissive
promoter chromatin states supporting transcriptional upregulation. To understand the chromatin states associated with
ASXL1 mutations, we integrated data on histone modiﬁcations
(H3K4me1, H3K4me3, H3K27ac, and H3K27me3 ChIP-seq) and
chromatin accessibility (ATAC-seq) by ﬁtting a 7-state hidden
Markov model (Fig. 3a)18. First, we contrasted the two genotypes
by subtracting the ASXL1WT from the ASXL1MT chromatin
states. This genome-wide analysis revealed a transition of poised
promoters and promoters with isolated chromatin accessibility to
active promoters (loss of state 01 and 04, gain of state 05). This
transition was mainly driven by H3K27ac and H3K4me1 gains in
promoter regions. To verify that changes in promoter occupancy
by the discovered chromatin states could serve as a plausible
explanation for the observed transcriptional activity, we tested the
associations between the presence of chromatin states and gene
expression in ASXL1MT CMML. As expected, the presence of
active chromatin states was associated with increased gene
expression (Fig. 3b). Conversely, the presence of poised and
repressed chromatin states was associated with decreased gene
expression. There was a dosage effect with greater promoter
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Fig. 1 Truncating ASXL1 mutations are of prognostic signiﬁcance in chronic myelomonocytic leukemia and frequently co-occur with other mutations. a
Flowchart showing the study design: An integrated multi-omics approach to discover ASXL1MT-speciﬁc epigenetic regulatory mechanisms associated with
transcriptional up-regulation. b Lollipop plot showing that all mutations in ASXL1 resulted in a frameshift preserving the HB1, ASXL, restriction endonuclease
helix-turn-helix (HARE) and LXXLL motif alpha helical (ASXH) domain but not the plant homeodomain (PHD). All observed variant allele frequencies were
compatible with heterozygosity. c Heatmap showing the spectrum of co-mutations, which included spliceosome components, chromatin regulators,
modulators of DNA methylation, and cell signaling molecules. The prevalence of abnormal karyotypes and the burden of co-mutations were similar
between ASXL1MT and ASXL1WT patients. d Kaplan–Meier plot showing overall survival estimates for the 375 patients with chronic myelomonocytic
leukemia from which the 16 patients in this study were sampled from (median follow-up 18 months). The presence of truncating ASXL1 mutations was
associated with increased all-cause mortality in this patient population (median overall survival 1.72 years, 95% CI 1.51–2.19, n = 202 versus 2.92 years,
95% CI 2.39–3.61, n = 173; HR 1.54, 95% CI 1.19–1.98, p = 0.001). This association remained consistent after adjusting for age at diagnosis, sex, and the
other factors of the Mayo Molecular Risk Stratiﬁcation Model (HR 1.37, 95% CI 1.05–1.78, p = 0.019, n = 375)8. There were no violations of the
proportional hazards assumption (p = 0.113). Source data are provided as a Source Data ﬁle.

region occupancy of a given state being associated with a greater
magnitude of this effect in the expected direction (Fig. 3c). Based
on this model, promoter chromatin state transitions may serve as
a plausible explanation for the observed changes in gene
expression in ASXL1MT CMML. Since the majority of the genes
included in this genome-wide analysis were not expressed at all or
not differentially expressed between the two genotypes, we performed a stratiﬁed analysis for the 707 up-regulated and 122
down-regulated genes in the ASXL1MT patients identiﬁed by
differential gene expression analysis (Fig. 3d). Among the downregulated genes there were chromatin state transitions between
ASXL1MT and ASXL1WT CMML involving a loss of poised
chromatin (01) and chromatin with isolated accessibility (04)
towards both active (05) and repressed states (02). Among the upregulated genes there was a marked increase of the active

promoter state (05) around the transcription start site and losses
of active chromatin states (05, 06) in the ﬂanking regions. We did
observe a gain in active chromatin states and / or loss of poised
and repressed chromatin states in the promoter regions of the
majority of up-regulated genes including mitotic kinases and
several HOXA cluster genes (Fig. 3e). However, for some genes
(particularly two groups of relatively lowly expressed genes) we
did not observe marked changes in promoter chromatin states
between ASXL1WT and ASXL1MT CMML. Signal tracks for select
up-regulated genes are shown in Supplementary Figure 3e.
Importantly, some of the chromatin state transitions observed
among the up-regulated genes (Fig. 3e) were not obvious when
performing the genome-wide analysis (Fig. 3a). Consistent with
previous observations, 5mC and 5hmC occupancy did not change
signiﬁcantly in the promoter regions of the differentially
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Table 1 Clinical characteristics of 16 patients with CMML
stratiﬁed by ASXL1 genotype.
Parameter

Unit

Age at diagnosis
[years]
Male sex
[n (%)]
Hemoglobin
[g/dL]
Leukocytes
[x109/L]
Neutrophils
[x109/L]
Lymphocytes
[x109/L]
Monocytes
[x109/L]
Platelets
[x109/L]
Peripheral blood blasts [%]
Bone marrow blasts
[%]
Abnormal
[n (%)]
cytogenetics
Morphology (WHO 2016)
CMML-0
[n (%)]
CMML-1
[n (%)]
CMML-2
[n (%)]
Mayo Prognostic Model
Low
[n (%)]
Intermediate
[n (%)]
High
[n (%)]
Mayo Molecular Model
Low
[n (%)]
Intermediate-1
[n (%)]
Intermediate-2
[n (%)]
High
[n (%)]
Leukemic
[n (%)]
transformation

ASXL1WT
(n = 8)

ASXL1MT
(n = 8)

66 (12)
4 (50)
12.3 (3.3)
8.4 (9)
3.2 (3.8)
2.3 (2.1)
2.0 (4.5)
112 (60)
0 (2)
4 (3)
3 (38)

67 (13)
6 (75)
11.6 (4.4)
14.2 (23.9)
6.5 (15.2)
1.9 (1.4)
2.8 (2.5)
159 (151)
0 (1)
2 (5)
3 (38)

5 (62)
1 (13)
2 (25)

4 (50)
3 (37)
1 (13)

3 (37)
2 (25)
3 (38)

0 (0)
4 (50)
4 (50)

3 (37)
2 (25)
3 (38)
0 (0)
4 (50)

0 (0)
0 (0)
4 (50)
4 (50)
5 (63)

Data are given as median (interquartile range) unless denoted otherwise.

expressed genes (Supplementary Fig. 3a–d)19. These data support
the notion that promoter chromatin state transitions between
ASXL1WT and ASXL1MT CMML are a plausible explanation for
the up-regulation of gene expression in ASXL1MT CMML. On
average, the transition from inactive to active promoter chromatin states is strongly associated with increased transcriptional
activity, but considerable heterogeneity exists among the upregulated genes.
Transcriptional up-regulation in ASXL1MT CMML is independent of gene body (hydroxy)methylation. Given this heterogeneity of promoter chromatin states across the up-regulated
genes, we sought to interrogate potential alternative epigenetic
regulatory mechanisms that may explain the observed transcriptional activity. Aberrant genome-wide DNA methylation is
associated with adverse cytogenetics features, increased leukemic
transformation rates, and inferior survival outcomes in CMML20.
However, differential DNA methylation in CMML is known to
predominantly affect hematopoiesis-speciﬁc enhancers rather
than promoter regions and gene bodies19,21. Not having observed
differences in (hydroxy)methylation of promoter regions of the
up-regulated genes (Supplementary Fig. 3a–d), we interrogated
gene body (hydroxy)methylation next. Gene body methylation
was strongly associated with increased transcriptional activity
(Fig. 4a). However, there was no differential gene body methylation between ASXL1WT and ASXL1MT CMML for either the
up- (Fig. 4b) or down-regulated genes (Fig. 4c). Similarly, gene
body hydroxymethylation was strongly associated with increased
transcriptional activity (Fig. 4d). Again, there was no differential
gene body hydroxymethylation between ASXL1WT and ASXL1MT
CMML for either the up- (Fig. 4e) or down-regulated genes
4

(Fig. 4f). In addition to the lack of differential (hydroxy)methylation in these stratiﬁed analyses, the co-mutations that might
affect DNA (hydroxy)methylation were relatively balanced
between the two ASXL1 genotypes (Fig. 1c). To ensure that the
presence of TET2, DNMT3A, or IDH2 co-mutations did not
confound the (hydroxy)methylation status, we performed a
stratiﬁed analysis that demonstrated no signiﬁcant difference in
global DNA (hydroxy)methylation (Supplementary Figure 4a).
We further validated these results using methylation microarrays
(Supplementary Fig. 4b, c). While transcriptional activity
increased both in the presence of gene body methylation and
hydroxymethylation, the effects of the extent of methylation and
hydroxymethylation on gene expression were different. While a
greater extent of gene body methylation was associated with
increased transcriptional activity (dosage effect), there was no
such relationship for hydroxymethylation (threshold effect,
Fig. 4g). Representative signal tracks for select genes of interest
are shown in Fig. 4h. As an alternative unbiased approach, we
identiﬁed 1595 differentially methylated regions (DMR, regions
with FDR < 0.05) in the validation data set (microarray data). We
mapped all hypermethylated regions to gene bodies requiring that
there was no concurrent hypermethylation of the promoter
region of the same gene. With this approach we identiﬁed one of
the 707 up-regulated single genes (0.14%) with evidence of isolated gene body hypermethylation (HBZ, log2-fold change in gene
expression 4.25, FDR = 0.0008, DMR area=1.61, DMR FDR =
0.018). These data support the notion that gene body (hydroxy)
methylation is associated with increased gene expression. However, the lack of differential (hydroxy)methylation between
ASXL1WT and ASXL1MT for the up-regulated genes make it an
unlikely explanation for the observed increase in transcriptional
activity.
ASXL1MT-speciﬁc distal enhancers are independently associated with transcriptional activity. Cis-regulatory elements are
powerful regulators of transcription and frequently altered in
myeloid neoplasms22. Enhancers have been associated with
aberrant transcriptional activity and response to treatment in
CMML23. We identiﬁed candidate cis-regulatory elements by
integrating chromatin accessibility and histone acetylation data.
To explain increased transcriptional activity among ASXL1MT
patients, we hypothesized that the responsible cis-regulatory
elements would only be present in ASXL1MT but not ASXL1WT
CMML (genotype-speciﬁc cis-regulatory elements). Regions with
chromatin accessibility (ATAC-seq) which were concurrently
marked by H3K27ac and unique to ASXL1MT were considered
candidate regions (Fig. 5a, b). There was no evidence for
increased de-ubiquitination of H2AK119 in proximity of these
genomic regions (Supplementary Fig. 5a). The vast majority of
the identiﬁed regions (92%) were annotated in ENCODE, with
75% of these regions demonstrating a distal enhancer-like signature (Fig. 5c) and 2% being known super-enhancers24–27. Motif
discovery revealed that these regions were predicted to bind ETS
family transcription factors (Fig. 5d)28. Intersection with publicly
available ChIP-seq data conﬁrmed the presence of ETS family
transcription factors in these ASXL1MT-speciﬁc enhancer regions
(Fig. 5e)29. BRD4 was also among the top 20 enriched transcription factors (effect size 2.05, p < 2.22 × 10−16) and this
enrichment was slightly more pronounced in the super-enhancer
regions (effect size 2.59, p = 0.005). To associate the enhancers
with putative target genes, we used a neighboring gene approach
incorporating proximity on the linear genome, experimentally
determined regulatory domains, and localization within conserved topologically associating domains (TADs)30,31. We
excluded candidate regions overlapping with promoter regions
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Fig. 2 The transcriptome of ASXL1MT CMML is characterized by transcriptional up-regulation of key mitotic pathways and leukemogenic driver genes.
a Volcano plot showing a predominance of transcriptional up-regulation in ASXL1MT CMML with a limited number of genes being down-regulated. Upregulated therapeutic targets with therapeutic agents either being available or currently under development are labeled. Also labeled are the members of
the posterior HOXA cluster including the leukemogenic driver HOXA9 and its co-factor MEIS1 (bold). b Heatmap showing the separation of ASXL1MT and
ASXL1WT CMML by unsupervised hierarchical clustering of all differentially expressed genes with FDR < 0.010. c Circos plot showing the up-regulation of
mitotic activity and down-regulation of MHC class I mediated antigen presentation and cytotoxic T-cell activity in ASXL1MT CMML (red: up-regulated in
ASXLMT CMML, blue: up-regulated in ASXLWT CMML). Bar graph showing the top hits in each gene ontology category (GO: Gene Ontology; BP: Biological
Process; MF: Molecular Function; CC: Cellular Compartment). Axes represent the statistical signiﬁcance of the gene ontology terms and the size of the
markers is proportional to the number of genes per cluster.

and focused on distal enhancers (91% of the identiﬁed regions).
These 3214 ASXL1MT-speciﬁc distal enhancers were implicated
in 4981 cis-interactions with 3308 genes (Fig. 5f). Among these
3308 genes were 97 of the 707 up-regulated genes, an overlap
unlikely to have occurred by chance (p = 2.22 × 10−6). Among
these 97 up-regulated target genes were MEIS1 and 17 mitotic
kinases including CDK1, CCNE1, and CDC20 (signiﬁcant
enrichment of mitotic cell cycle process, GO:1903047, FDR =
0.011). By virtue of the applied selection algorithm (GREAT) and
additional constraints (TADs), most ASXL1MT-speciﬁc distal

enhancers were localized between 5 and 200 kb of their associated
target gene (Fig. 5g). The presence of a distal enhancer was
positively associated with the expression of its target gene without
evidence for a dosage effect when more than one enhancer was
associated with a target gene (Fig. 5h). The effect of the presence
of a distal enhancer on the expression of its target gene decreased
with increasing distance on the linear genome (Fig. 5i). The genes
associated with these ASXL1MT-speciﬁc distal enhancers were
involved in oncogenic MAPK and receptor tyrosine kinase signaling (Fig. 5j). To understand if the presence of these enhancers
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is independently associated with increased gene expression, we ﬁt
multivariable-adjusted linear regression models. Among patients
with ASXL1MT CMML, the presence of these distal enhancers
was independently associated with increased gene expression
(Supplementary Fig. 5b). The magnitude of this effect (the presence of an ASXL1MT-speciﬁc distal enhancer) was comparable to
a 20% increase in active promoter chromatin states or in gene
6

body methylation. A measure of the relative importance of the
different epigenetic regulatory mechanisms is shown in Supplementary Fig. 5c. Relevant regression diagnostics for the model are
shown in Supplementary Fig. 5d–f. These data support the notion
that ASXL1MT-speciﬁc distal enhancers are independently associated with increased oncogenic gene expression and their presence can serve as a plausible explanation for the observed
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Fig. 3 ASXL1MT CMML is associated with permissive promoter chromatin states supporting transcriptional up-regulation. a Heatmaps showing the
chromatin states discovered by hidden Markov modeling and the transition of chromatin states between ASXL1WT and ASXL1MT CMML. b Box and strip
plots showing the association between the presence of a given chromatin promoter state and gene expression (transcriptome-wide) among patients with
ASXL1MT CMML (two-sided Mann–Whitney U test, raw p-values without adjustment for multiple hypothesis testing shown). c Box and strip plots showing
the association between the extent of promoter occupancy of a given chromatin state and gene expression (transcriptome-wide) among patients with
ASXL1MT CMML (two-sided Cuzick’s test for trend, raw p-values without adjustment for multiple hypothesis testing shown). The associations shown in b
and c validate the model’s ability to predict gene expression and suggest that the transitions of these chromatin states between ASXL1WT and ASXL1MT
CMML may serve as a plausible explanation for the observed differences in gene expression. d Heatmaps showing the chromatin state transitions in
promoter regions between ASXL1WT and ASXL1MT CMML for the up- (n = 707) and down-regulated (n = 122) genes separately. e Scatter plots showing
the 707 up-regulated genes in two-dimensional tSNE space, clustered based on their promoter chromatin states. Color coding indicates the type of
promoter chromatin state transition affecting each gene between ASXL1WT and ASXL1MT CMML. Marker size indicates the median gene expression
among patients with ASXL1MT CMML. The HOXA genes, MEIS1, and the mitotic kinases are labeled. One representative gene from each group of promoter
chromatin state transitions is highlighted (bold print) and corresponding ChIP-seq signal tracks are shown in Supplementary Fig. 3e. Data are presented as
standard Tukey boxplots (with the box encompassing Q1 to Q3, the median denoted as a central horizontal line in the box, and the whiskers covering the
data within ±1.5 IQR in 3b and c).

increased transcriptional activity including the overexpression of
mitotic kinases.
ASXL1MT CMML is characterized by increased intratumoral
heterogeneity due to increased chromatin accessibility in
transcription factor binding sites. Having identiﬁed ETS family
transcription factors predicted to bind the ASXL1MT-speciﬁc
distal enhancers in proximity to several of the up-regulated genes,
we performed single-cell ATAC-seq on three patients with
ASXL1WT (6832 cells) and three patients with ASXL1MT CMML
(5360 cells) to validate our bulk ATAC-seq ﬁndings (Supplementary Fig. 6a–e). Cells from patients with ASXL1MT CMML
demonstrated increased chromatin accessibility as evidenced by
an extended repertoire of accessible transcription factor motifs
(Fig. 6b). Among the top motifs were key oncogenic myeloid
transcription factors including MZF1 (known to stimulate proliferation and delay differentiation), MEF2C (linked to therapeutic resistance), and MEIS1 (synergistic with HOXA9 in
inducing leukemogenesis)32–34. We hypothesized that the
increased chromatin accessibility could drive intratumoral heterogeneity in ASXL1MT CMML. We calculated measures of tissue
diversity and specialization for both genotypes and observed an
increase in diversity with a reciprocal decrease in specialization in
ASXL1MT CMML (Fig. 6c and d). When examining 1504
ASXL1MT-speciﬁc distal enhancers (identiﬁed by scATAC-seq),
we again observed an enrichment of ETS family transcription
factor motifs (Fig. 6e). Similarly, BRD4 was again among the top
5 enriched transcription factors in these regions (effect size 2.32,
p < 2.22 × 10−16). These data support the notion that ASXL1MT
CMML is characterized by an increase in intratumoral heterogeneity with increased chromatin accessibility for transcription
factors binding ASXL1MT-speciﬁc distal enhancers.
Discussion
The gene expression proﬁle of ASXL1MT CMML is characterized
by overexpression of proliferative genes, mirroring the clinical
phenotype of leukocytosis, splenomegaly, resistance to epigenetic
therapies (DNA methyltransferase inhibitors), and increased
leukemic transformation rates35. Gaining a better understanding
of the molecular mechanisms underlying this aberrant transcriptional activity is important for the development of novel
therapies for patients with ASXL1MT CMML. In this study we
interrogated the epigenome of patients with ASXL1MT CMML
and observed a transition from poised and inactive to active
chromatin states in promoter regions and increased chromatin
accessibility exposing de novo distal enhancers correlating with
the transcription of affected genes. We furthermore observed an

increase in intratumoral heterogeneity due to an extended
repertoire of transcription factor motifs, again involving
ASXL1MT-speciﬁc distal enhancers. These results suggest an
important role of oncogenic cis interactions for the sustained
expression of key drivers of leukemogenesis in ASXLMT CMML.
The three ASXL proteins (ASXL1, ASXL2 and ASXL3) are
mammalian homologs of Addition of sex combs (Asx) in Drosophila, a protein that regulates the balance of trithorax (activating) and polycomb (repressive) functions. In myeloid
neoplasms, the ASXL1 gene is frequently affected by nonsense
and frameshift mutations leading to truncation of the protein at
the C-terminus and loss of the plant homeodomain (PHD)15.
Hitherto, the associated proteins for the PHD of the Asx family
remain unknown36. Investigations employing different disease
models have shed light on the transcriptomic and epigenetic
changes associated with ASXL1 loss and truncation. ASXL1 is
thought to recruit chromatin modulators and transcription factors to alter transcriptional activity of genes involved in leukemogenesis. The exact molecular mechanisms associated with
truncating ASXL1 mutations however remain to be deﬁned. Based
on the interaction between ASXL1 and BAP1, a predominant loss
of polycomb repressive complex 1 (PRC1)-mediated histone deubiquitination was the initial expected mechanism regulating
transcriptional activity in ASXL1MT patients12,37. However,
observations in ASXL1MT AML cell lines suggested a predominant loss of polycomb repressive complex 2 (PRC2)-mediated histone methylation (loss of H3K27me3) to be the regulatory
mechanism at work and implicated the deregulation of posterior
HOXA cluster genes as key factors in the ensuing
leukemogenesis9. Observations from an ASXL1MT murine model
suggested a gain of function of PRC1-mediated effects rather than
altered PRC2 activity (unaffected H3K27me3)13. The notion that
increased de-ubiquitination is facilitating the transcriptional upregulation through enhanced activity of the ASXL1-BAP1 complex was further conﬁrmed in different ASXL1MT cell lines,
however, a decrease in H3K27me3 was observed at the same time
in this disease model11. Loss of both H3K27me3 and
H2AK119Ub promoting the expression of leukemogenic posterior HOXA genes has since been conﬁrmed in cell lines and a
murine model10. Another ASXL1MT murine model revealed an
increase in chromatin accessibility along with the recruitment of
the bromodomain and extra-terminal domain family member
BRD4, resulting in enhanced expression of genes involved in
stem-cell maintenance and myeloid differentiation14. Overall, the
sum of evidence from these mechanistic studies suggests that
ASXL1 has a complex interactome, that truncating ASXL1
mutations promote leukemogenesis by transcriptional upregulation of leukemogenic drivers including posterior HOXA
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genes, and that these mutations recruit several effectors to alter
the epigenome through histone modiﬁcations, increases in
chromatin accessibility, and remodeling of enhancers9–14.
Given the complexity of human transcriptional regulation
in vivo and the multitude of potential epigenetic mechanisms
cooperating to regulate transcriptional activity, we interrogated
the genome, transcriptome, and epigenome of ASXL1MT CMML
using primary patient samples. Employing conservative statistical
methods and relying on a robust number of biological replicates,
we observed signiﬁcant changes in promoter chromatin states and
distal enhancers in ASXL1MT CMML. In general, these changes
were less extreme than the ones observed in data generated from
different hematopoietic precursor and leukemic cell lines9,11. We
interpret these differences as a consequence of greater biological
variability in primary patient samples and the statistical framework employed in this study. While previous studies have focused
8

on global changes in histone modiﬁcations and considered them
in isolation, we integrated several omics layers using an unbiased
machine learning approach to capture the complexity of the
epigenetic landscape to a greater extent. In doing so, we observed
signiﬁcant differences between global trends in chromatin
remodeling and changes affecting the differentially expressed
genes of interest. This may indicate that global assessments of
chromatin remodeling are only part of the information required
to develop effective targeted epigenetic therapies for speciﬁc
leukemogenic mechanisms. For many of the up-regulated genes,
we observed chromatin state transitions towards active states
driven by H3K27ac deposition in promoter regions. Similarly, we
observed a loss of H2K27me3 affecting the promoter regions of
several of the up-regulated genes (either in isolation or in concert
with the aforementioned gains in active chromatin states). For
several up-regulated, yet relatively lowly expressed genes the

NATURE COMMUNICATIONS | (2022)13:1434 | https://doi.org/10.1038/s41467-022-29142-6 | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-29142-6

ARTICLE

Fig. 4 Gene body (hydroxy-)methylation is positively associated with gene expression but cannot serve as an explanation for the increased
transcriptional activity given the lack of differential (hydroxy-)methylation between ASXL1 genotypes. a Box and strip plots showing the association
between the extent of gene body methylation and gene expression (transcriptome-wide) among patients with ASXL1MT CMML (two-sided Cuzick’s test
for trend, raw p-values without adjustment for multiple hypothesis testing shown). b Bar graphs showing the lack of differential gene body methylation
between ASXL1WT and ASXL1MT CMML for the up-regulated genes. c Bar graphs showing the lack of differential gene body methylation between ASXL1WT
and ASXL1MT CMML for the down-regulated genes. d Box and strip plots showing the association between the extent of gene body hydroxymethylation and
gene expression (transcriptome-wide) among patients with ASXL1MT CMML. e Bar graphs showing the lack of differential gene body hydroxymethylation
between ASXL1WT and ASXL1MT CMML for the up-regulated genes. f Bar graphs showing the lack of differential gene body hydroxymethylation between
ASXL1WT and ASXL1MT CMML for the down-regulated genes. g Scatter plot showing the association between the extent of gene body (hydroxy)
methylation and gene expression among patients with ASXL1MT CMML. Gene expression increases linearly with increases in gene body methylation. While
the presence (compared to the absence) of gene body hydroxymethylation is strongly associated with increased gene expression, a greater extent of gene
body hydroxymethylation is not associated with further increases in gene expression (threshold). The two-sided Wald test was used to test the model
coefﬁcients (raw p-values without adjustment for multiple hypothesis testing are shown). h Signal tracks showing the lack of differential (hydroxy-)
methylation between ASXL1WT and ASXL1MT CMML for the up-regulated genes HOXA7 and HOXA9. Data are presented as mean values (bars in 4b, c, e,
f) or standard Tukey boxplots (with the box encompassing Q1 to Q3, the median denoted as a central horizontal line in the box, and the whiskers covering
the data within ±1.5 IQR in 4a–f). The two-sided Mann–Whitney U test was used to compare groups in 4b–f, raw p-values without adjustment for multiple
hypothesis testing are shown.

model did not reveal marked state transitions in the promoter
regions. The global increase in the active promoter state also
included gains in H3K4me1, which is of particular interest since
KMT2A fusions, partial tandem duplications, abnormalities of
KMT2C/KMT2D/SET1D/2D (COMPASS family) are exceedingly
rare in CMML38. Another open question concerns the locusspeciﬁc effects of truncating ASXL1 mutations. While we
observed widespread remodeling of the epigenome, we do not
fully understand how truncated ASXL1 exerts its effects selectively across the epigenome. This represents a limitation of the
current study and future work in suitable disease models may
help further reﬁne the list of targets of truncated ASXL1. While
ChIP-seq studies with antibodies directed against truncated
ASXL1 may reveal genomic loci of direct interaction, other
ASXL1-mutant-speciﬁc effects may be mediated through proteinprotein interactions39,40. Furthermore, our gene expression data
did not support the gene expression proﬁles observed in different
murine myeloid disease models (e.g. lack of HHEX up- and lack
of SOX6 down-regulation in ASXL1MT CMML) and it remains
debatable how closely these models recapitulate human disease
biology, given the inherent heterogeneity of human myeloid
neoplasms13,41. In search of additional regulatory mechanisms for
the up-regulated genes, we revisited promoter and gene body
methylation without discovering compelling evidence for either
mechanism being at work in ASXL1MT CMML, despite the high
prevalence of concurrent TET2 mutations35. This is consistent
with previous observations in CMML pointing towards the
importance of hematopoiesis-speciﬁc enhancers and may further
be explained by the relatively balanced distribution of comutations in this study19,21. In CMML, aberrant methylation is
known to be associated with distinct clinical features such as
high-risk karyotypes and therapeutic resistance20,23. At the same
time, the most commonly employed treatment strategy for
CMML is the inhibition of DNMT with DNA methyltransferase
inhibitors (i.e. azacytidine ± cedazuridine, decitabine), which are
thought to epigenetically restore normal hematopoiesis in a
subset of patients without altering the mutational burden or
inherent risk of leukemic transformation42–44. Furthermore,
subsequent translational investigations in CD14-selected peripheral blood mononuclear cells demonstrated that differential
promoter methylation does not correlate with transcription in
CMML45. Our DNA immunoprecipitation and microarray
methylation studies using unselected bone marrow mononuclear
cells do conﬁrm these ﬁndings, so do our RNA-seq results in
CD34-selected, CD14-selected, and unselected bone marrow
mononuclear cells. Extending the search for plausible additional

regulatory mechanisms, we discovered a group of distal enhancers
with interesting characteristics. First, these enhancers were speciﬁc for ASXL1MT CMML. Second, these enhancers associated
with several of the genes up-regulated in ASXL1MT CMML.
Third, these enhancers tightly correlated with transcription
independent of the prevalent promoter chromatin states and gene
body (hydroxy)methylation. A model including promoter chromatin states, ASXL1MT-speciﬁc distal enhancers, and gene body
(hydroxy)methylation explained almost half of the variation in
gene expression and adds to our understanding of the complexity
of transcriptional regulation in ASXL1MT CMML. These
ASXL1MT-speciﬁc distal enhancers were highly enriched in ETS
family transcription factor motifs as well as BRD4 and explained
part of the observed increase in intratumoral heterogeneity at the
single-cell level. The mapping of these enhancers and their
association with key up-regulated leukemogenic drivers such as
MEIS1 and several mitotic kinases is of considerable interest
given that the presence of such enhancers represents an explanation for the lineage- and context-speciﬁc transcriptional effects
of novel therapeutic agents such as BET bromodomain
inhibitors46,47. Observing BRD4 enrichment in the ASXL1MTspeciﬁc distal (super-)enhancers, further support the exploration
of these novel therapeutics for individualized treatment approaches in ASXL1MT CMML. Here we drew a detailed map of
oncogenic distal enhancers unique to a high-risk phenotype of
CMML, laying the foundation for future mechanistic studies
deﬁning the viability of these aberrant cis interactions to serve as
therapeutic targets. Genotype-speciﬁc oncogenic chromatin
interactions may be exploited for therapeutic beneﬁt and serve as
the rationale for early phase clinical trials with emerging epigenetic small molecule therapeutics in a disease that has not seen
signiﬁcant therapeutic advances in the last 25 years48–51.
Methods
Patient population, sample acquisition, and cell selection. To survey the (epi-)
genetic landscape of human CMML, we obtained bone marrow mononuclear cells
from 16 patients with WHO-deﬁned CMML (Table 1), half of which had truncating ASXL1 mutations. We performed targeted next generation sequencing of
DNA, whole transcriptome RNA sequencing (RNA-seq), immunoprecipitation of
DNA hydroxymethyl and methyl residues (DIP-seq), immunoprecipitation of the
histone modiﬁcations H2AK119ub, H3K4me1, H3K4me3, H3K27ac, and
H3K27me3 (ChIP-seq), and DNA transposase accessibility assays (ATAC-seq).
The RNA-seq data were used to deﬁne the transcriptional activity in ASXL1MT
CMML and then correlated with known epigenetic regulatory mechanisms by
integrating the ChIP-, DIP-, and ATAC-seq data. CMML is a malignant proliferation of monocytes and, unlike in acute myeloid leukemia, the fraction of
CD34+ blasts is usually below 5%35. CD14 on the other hand is a marker of
terminally differentiated monocytes as they appear in the peripheral blood and it is
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debatable whether the CD14+ cell population in the bone marrow represents the
malignant cell population of interest in CMML. We refrained from further CD34or CD14-sorting the bone marrow mononuclear cells for several reasons: First, the
cell attrition rates due to CD34- and CD14-sorting would have made the multiomics interrogation of primary patient samples for this study impossible (particularly the cell requirements for the ChIP-seq experiments). Second, we observed a
tight correlation between the gene expression proﬁles of sorted and unsorted cells,
raising the question whether cell sorting would have inﬂuenced the results signiﬁcantly (Supplementary Fig. 2a–c). Third, our methylation analysis on unsorted
10

cells conﬁrms the results generated from CD14-sorted monocytes45. Avoiding
excessive cell attrition due to sorting, we have been able to perform all analyses
with at least ﬁve biological replicates per group. There were 16 patients included in
this study and we performed experiments on all available samples for these
patients. Supplementary Fig. 1c shows the samples that were included in the
analysis after performing sample and data quality control. There were 14 samples
for RNA-seq (87.5%), 15 for H2AK119ub ChIP-seq (93.8%), 15 for H3K27ac
ChIP-seq (93.8%), 12 for H3K27me3 (75.0%), 14 for H3K4me1 ChIP-seq (87.5%),
11 for H3K4me3 ChIP-seq (68.8%), 15 for 5mC DIP-seq (93.8%), 15 for 5hmC
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Fig. 5 ASXL1MT-speciﬁc distal enhancers are positively associated with gene expression of their putative target genes and can serve as a plausible
explanation for the increased transcriptional activity in ASXL1MT CMML. a Venn diagram showing the co-mapping of chromatin accessibility and
H3K27ac to identify ASXL1MT-speciﬁc cis-regulatory elements. b Signal curves and heatmaps showing the co-occurrence of DNA accessibility and
H3K27ac in these ASXL1MT-speciﬁc cis-regulatory elements. c Venn diagram and bar graphs demonstrating the identity of these ASXL1MT-speciﬁc cisregulatory elements (known enhancers, mostly distally located). d Position weight matrices generated from motif discovery show the over-representation
of ETS transcription factors (top 5 enriched motifs) in the ASXL1MT-speciﬁc distal enhancers. e Validation of the predicted ETS transcription factor
enrichment in the ASXL1MT-speciﬁc distal enhancers using publicly available human transcription factor ChIP-seq data. f Euler diagrams and bar graphs
showing the association between the ASXL1MT-speciﬁc distal enhancers and putative target genes within leukemia-speciﬁc topologically associating
domains. g Bar graphs showing the distribution of the ASXL1MT-speciﬁc distal enhancers by distance on the linear genome from the transcription start site
of their putative target genes. h Box and strip plots demonstrating the association between the presence of distal enhancers and increased gene expression
among patients with ASXL1MT CMML (without evidence for a dosage effect of more than one distal enhancer). i Box and strip plots demonstrating the
association between proximity of distal enhancer and putative target gene on the linear genome and increased gene expression of the putative target gene
among patients with ASXL1MT CMML. j Bar graphs showing the functional annotation of the putative target genes of the ASXL1MT-speciﬁc distal enhancers
including receptor tyrosine kinase, cytokine, and oncogenic MAPK signaling. Data are presented as standard Tukey boxplots (with the box encompassing
Q1 to Q3, the median denoted as a central horizontal line in the box, and the whiskers covering the data within ±1.5 IQR in 5h and i).

Fig. 6 ASXL1MT CMML is associated with increased intratumoral heterogeneity secondary to an extended repertoire of accessible distal enhancers. a
Scatter plot showing 12192 single cells from CMML patients (stratiﬁed by ASXL1 genotype) in two-dimensional tSNE space, clustered based on the
accessibility of known transcription factor motifs. b Bar graphs and dot plot demonstrating the increased single-cell accessibility of binding sites for 476
transcription factors (top panel), ranked by the difference in accessible transcription factor motif (TFM) binding sites (scATAC-seq peaks with a given
transcription factor motif) between ASXL1WT and ASXL1MT CMML. The top 50 transcription factors with increased accessible binding sites are magniﬁed
(bottom panel) and included key oncogenic myeloid transcription factors such as MZF1, MEF2C, and MEIS1. Source data are provided as a Source Data ﬁle.
c Area graphs and box plots showing a measure of tissue diversity (based on single-cell entropies) for 12192 single cells from CMML patients (stratiﬁed by
ASXL1 genotype). The two-sample Kolmogorov-Smirnov test for equality of distribution functions was used to compare both distributions. Source data are
provided as a Source Data ﬁle. d Area graphs and box plots showing a measure of tissue specialization (based on single-cell entropies) for 12192 single
cells from CMML patients (stratiﬁed by ASXL1 genotype). The two-sample Kolmogorov-Smirnov test for equality of distribution functions was used to
compare both distributions (p-value). Source data are provided as a Source Data ﬁle. e Bar graphs showing the enrichment of ETS transcription factor
motifs in 1504 ASXL1MT-speciﬁc distal enhancers identiﬁed by scATAC-seq (validation of bulk ATAC-seq ﬁndings). Data are presented as standard Tukey
boxplots (with the box encompassing Q1 to Q3, the median denoted as a central horizontal line in the box, and the whiskers covering the data within ±1.5
IQR in 6c and d).
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DIP-seq (93.8%), and 11 for ATAC-seq (68.8%). The 16 patients included in this
study were sampled from a population of 576 patients with WHO-deﬁned CMML
seen at the Mayo Clinic in Rochester, Minnesota52. All studies were approved by
the Mayo Clinic Institutional Review Board. Written informed consent was
obtained from all patients in accordance with the Declaration of Helsinki. Bone
marrow mononuclear cells were collected in EDTA tubes and selected using FicollHypaque density gradient centrifugation (Sigma-Aldrich, St. Louis, United States).
Genomic DNA was isolated using the ACCEL-NGS 1 S Plus DNA Library Kit
(Swift Biosciences, Ann Arbor, United States). Total RNA was analyzed by preparing cDNA libraries generated in accord with the RNA-seq preparation protocol
(Illumina, San Diego, United States). Viable bone marrow mononuclear cells were
stored in freezing medium (10% DMSO, 40% fetal bovine serum, 40% RPMI) at
−80 °C.
DNA targeted next-generation sequencing. For 375 of the 576 patients complete
clinical information as well as genetic information from a 36-gene panel targeted
next-generation sequencing assay were available for prognostic modeling. The
regions of these 36 genes were selected for custom target capture using Agilent
SureSelect Target Enrichment Kit (Agilent Technologies, Santa Clara, United
States). Libraries derived from each DNA sample were prepared using NEB Ultra II
(New England Biolabs, Ipswitch, United States) and individually barcoded by dual
indexing. Sequencing was performed on an HiSeq 4000 (Illumina) with 150 bp
paired-end reads. Forty-eight pooled libraries per lane were sequenced to a median
read depth of ~400x. The custom panel of target regions covered all coding regions
and consensus splice sites from the following 36 genes: ASXL1, CALR, CBL,
CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, IKZF1, JAK2, KRAS, MPL, NPM1,
NRAS, PHF6, PTPN11, RUNX1, SETBP1, SF3B1, SH2B3, SRSF2, TET2, TP53,
U2AF1, and ZRSR2. Paired-end reads were processed and analyzed as previously
described8.

RNA-seq and qPCR. RNA quality was determined using an Agilent Bioanalyzer
RNA Nanochip or Caliper RNA assay. Library preparation was performed using
TruSeq Stranded Total RNA (Illumina) and sequenced on an HiSeq 2500 (Illumina) with paired-end reads. RNA-seq sequencing reads were processed through
the MAPRSeq bioinformatics workﬂow as previously described53. Reads were
aligned to the GRCh38 reference genome and transcript counts calculated using
featureCounts (v2.0.0)54. Differential expression was performed using DESeq2
(v1.30.1), clustering using heatmap.2 (v3.1.1, https://CRAN.R-project.org/
package=gplots), and plotting using EnhancedVolcano (v1.8.0, https://github.com/
kevinblighe/EnhancedVolcano)55. Pathway analyses were performed using gProﬁler (v2021-05-01) and the Reactome Pathway Knowledgebase (v2021-5-7)56,57.
Potential therapeutic targets among the up-regulated genes were identiﬁed by
querying DGIdb (v3.0)17. For the validation of RNA-seq results we analyzed a
subset of target genes by quantitative Reverse Transcription Polymerase Chain
Reaction (RT-qPCR). Total RNA from the RNA-seq experiments was used to
synthetize cDNA with the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Carlsbad, United States). A 1/3 dilution of the total cDNA
was ampliﬁed by real-time PCR. Samples were prepared with PerfeCTa SYBR
Green FastMix (Quanta BioSciences, Gaithersburg, United States), the primer sets
are given in Supplementary Data 1.

ChIP-seq. Approximately 100,000 cells from each sample were used for input for
native chromatin immunoprecipitation (N-ChIP). Cells were lysed on ice for
20 min in lysis buffer containing 0.1% Triton X-100, 0.1% deoxycholate, and
protease inhibitor. Extracted chromatin was digested with 90U of MNase enzyme
(New England Biolabs) for 6 min at 25 °C. The reaction was quenched with 250 µM
of EDTA post-digestion. A mix of 1.0% Triton X-100 and 1.0% deoxycholate was
added to the digested samples and incubated on ice for 20 min. Digested chromatin
was pooled and pre-cleared in IP buffer (20 mM Tris-HCl [pH 7.5], 2 mM EDTA,
150 mM NaCl, 0.1% Triton X-100, and 0.1% deoxycholate) plus protease inhibitors
with pre-washed Protein A/G Dynabeads (Thermo Fisher Scientiﬁc, Waltham,
United States) at 4 °C for 1.5 h. Supernatants were removed from the beads and
transferred to a 96-well plate containing the antibody-bead complex. Following an
overnight 4 °C incubation, samples were washed twice with low salt buffer (20 mM
Tris-HCl [pH 8.0], 0.1% SDS, 1.0% Triton X-100, 2 mM EDTA, and 150 mM
NaCl) and twice with high salt buffer (20 mM Tris-HCl [pH 8.0], 0.1% SDS, 1.0%
Triton X-100, 2 mM EDTA, and 500 mM NaCl). DNA-antibody complexes were
eluted in elution buffer (100 mM NaHCO3, 1.0% SDS), incubated at 65 °C for
90 min. Protein digestion was performed on the eluted DNA samples at 50 °C for
30 min using protease mix (QIAGEN, Venlo, Netherlands). ChIP DNA was puriﬁed using Sera-Mag beads (Thermo Fisher Scientiﬁc) with 30% PEG before library
construction. H2AK119ub and H3K27ac ChIP-seq was performed as previously
described58. The antibodies were used at a dilution of 1:250 (H3K27me3), 1:500
(H3K4me1 and H3K4me3), and 1:1000 (H2AK119ub and H3K27ac). Libraries
were prepared by following a modiﬁed Illumina paired-end protocol and
sequenced on an HiSeq 2500 (Illumina) to a median depth of ~25 million
(H3K4me1 and H3K4me3) or ~50 million reads (H3K27me3 and Input). Reads
were aligned to the GRCh38 reference genome using bowtie2 (v2.3.3.1)59.
12

DIP-seq and methylation microarrays. Genomic DNA was isolated and submitted to the Mayo Clinic Epigenomics Development Laboratory (EDL) for DNA
immunoprecipitation and library preparation. The 5mC-33D3 (C15200081)
monoclonal antibody (Diagenode, Denville, United States), an in-house developed
5hmC antibody (EDL), and the 53017 bridging antibody (Active Motif, Carlsbad,
United States) were used. The antibodies were used at a dilution of 1:110 (5hmC)
and 1:340 (5mC). Libraries were prepared by following a modiﬁed Illumina pairedend protocol and sequenced on a HiSeq 4000 (Illumina). Reads were aligned to the
GRCh38 reference genome using the Burrows-Wheeler Aligner60. For the validation of DIP-seq results we analyzed a subset of samples on the Inﬁnium MethylationEPIC (850 K) array (Illumina) according to the manufacturer’s speciﬁcations.
Signal intensities were processed and normalized using Minﬁ (v1.36.0) using subset
within-array quantile normalization61,62. CpGs below the detection threshold
(p < 0.010) as well as unreliable and cross-reactive probes were removed, leaving
787403 CpGs for downstream analyses. Differentially methylated regions were
identiﬁed using bumphunter (v1.32.0)63.
ATAC-seq and single-cell ATAC-seq. DNA for ATAC-seq was prepared from
50,000 cells following the OMNI-ATAC procedures as described by Corces et al.
with modiﬁcations using the Nextera kit (Illumina)64. The cells were lysed for
3 min on ice and transposed for 30 min at 37 °C following clean-up. The DNA
libraries were prepared with 5–10 cycles of PCR ampliﬁcation with the NEB High
Fidelity Master Mix (New England Biolabs, Ipswich, United States). Clean-up was
done using the Zymo DNA Clean and Concentrator kit (Zymo Research, Irvine,
United States) and followed with AMPure XP (Beckman Coulter, Brea, United
States) bead clean-up to remove primer dimers and under-digested chromatin.
Sequencing was performed on an HiSeq 4000 (Illumina) to a depth of ~30 million
reads per sample. Reads were aligned to GRCh38 using bowtie259. For the singlecell chromatin transposase accessibility assays (scATAC-seq) cryopreserved bone
marrow mononuclear cells were thawed and resuspended following an established
workﬂow (thawing, resuspension, sequential dilution, centrifugation, straining,
viability assessment) and approximately 100000 viable mononuclear cells per
sample were subjected to transposase assays (exposing buffered nuclei to Tn5
transposase) before proceeding to single-cell partitioning into gel beads in emulsion, barcoding, library construction, and sequencing following established 10X
Genomics protocols. The target cell recovery was approximately 2000 cells per
sample. For details on the 10X Genomics Chromium platform including demonstrated protocols on sample preparation, library construction, instrument settings,
and sequencing parameters please see the manufacturer’s resources (https://
support.10xgenomics.com/single-cell-atac). Genomic libraries were sequenced on
an HiSeq 4000 (Illumina) before demultiplexing, alignment to the reference genome, and post-alignment quality control. The 10X Genomics Cell Ranger ATAC
software (v2.0) was used for demultiplexing, alignment of the reads to the GRCh38
reference genome, ﬁltering and quality control, counting of barcodes and unique
molecular identiﬁers, identiﬁcation of transposase cut sites, detection of accessible
chromatin peaks, count matrix generation for peaks and transcription factors.
Consensus peak calling. Aligned reads from the different immunoprecipitation and
accessibility sequencing experiments were sorted and indexed using samtools (v1.9)
and peaks were called using MACS2 (v3.0.0a6) with input controls (except ATACseq)65,66. Peak calling with default parameters was performed before subjecting the
peaks to the MSPC (v5.4.0) consensus peak calling algorithm67. By convention
H3K4me1, H2AK119ub, and H3K27me3 peaks were called as “broad peaks” and the
remaining marks were called as “narrow peaks”. To leverage the power of several
biological replicates per analysis we employed a standard peak calling threshold in
MACS2 (FDR < 0.050) before applying a more stringent threshold in the subsequent
MSPC step (weak threshold p < 1.00 × 10−4, stringency threshold p < 1.00 × 10−8).
The UCSC Genome Browser and deepTools (v3.5.0) were used for signal
visualization68,69. For visualization purposes averaged, input-corrected average signal
tracks were created (except ATAC-seq where no input was used) using wiggletools
mean (v1.2) and deepTools bamCoverage / bigwigCompare70.
Data analysis. Data are presented as median (range) unless denoted otherwise.
Medians were the preferred measure of central tendency and non-parametric
hypothesis tests were used for comparisons unless stated otherwise. Continuous
variables were compared using the Mann-Whitney-U test, categorical variable using
Fischer’s exact test. Trends across ordered groups were assessed using Cuzick’s test
for trend. The equality of single-cell entropy distributions was evaluated using the
two-sample Kolmogorov-Smirnov test. Overall and leukemia-free survival estimates
were calculated using the Kaplan and Meier method71. Overall survival was deﬁned
as the time from diagnosis to death and patients who were alive at the end of followup were censored. Leukemia-free survival was deﬁned as the time from diagnosis to
leukemic transformation or death and patients who were alive and free of acute
leukemia at the end of follow-up were censored. The log-rank test was used to
compare time to event data in subgroups. Multivariable-adjusted (Cox) proportional
hazards regression models were used to assess the association between clinical and
genetic parameters of interest and overall survival72. Violations of the proportional
hazards assumption were evaluated using Schoenfeld residuals. Hidden Markov
modeling (ChromHMM v1.22) was used to discover and characterize the presence of

NATURE COMMUNICATIONS | (2022)13:1434 | https://doi.org/10.1038/s41467-022-29142-6 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-29142-6

chromatin states in promoter regions (TSS ± 2000bp)18. We ﬁt 5- to 15-state models
and judged their goodness of ﬁt by each model’s ability to discriminate important
chromatin states (active promoter, poised promoter, active enhancer, inactive
enhancer, repressed, quiescent) without creating an excessive number of combinatorial states within each epigenetic mark. Based on the ability to sufﬁciently discriminate the activity of promoters and enhancers, the 7-state model was felt to be
the most parsimonious model with acceptable ﬁt for the data. Candidate cisregulatory elements were validated using the ENCODE, GeneHancer, and Hacer
databases24,25,27. To annotate and associate these regions with potential target genes,
the Genomic Regions Enrichment of Annotations Tool (GREAT v4.0.4) was used30.
To increase the speciﬁcity of the predicted (enhancer-promoter) cis-interactions, we
included only those that did not violate the boundaries of topologically associating
domains established in K562 cells31. Super-enhancers were identiﬁed by intersecting
the candidate cis-regulatory elements with known super-enhancers in K562 cells26.
De novo motif analysis was performed using Hypergeometric Optimization of Motif
EnRichment (HOMER v3.0)28. Candidate transcription factors predicted to bind
these regions were then validated by querying the ReMap 2020 database29. To
estimate the independent effect of each epigenetic regulatory mechanism on gene
expression, we employed multivariable-adjusted linear regression. Given the heavily
left-skewed distribution and overdispersion of transcript count data we performed a
log-transformed of the transcript count data (adding a pseudocount). We then used
ordinary least squares regression to model the transformed transcript count data and
exponentiated the obtained regression coefﬁcients for ease of interpretation of the
effect sizes (eβ − 1). The model included the active and inactive chromatin states,
gene body (hydroxy)methylation, and the presence of an associated distal enhancer
as parameters. We used the lmg metric (hierarchical partitioning of R2) as an estimate of relative importance for each model paramaters73,74. Routine regression
diagnostics were employed to evaluate model assumptions and model ﬁt (including
assessments of inﬂuence, leverage, and multicollinearity). Observations with excessive leverage (h > [(2 * k)/n]) and inﬂuence (Cook’s D > [4/(n − k − 1)]) were
removed (n denoting the sample size and k the number of model parameters).
Quality control, integration, normalization (TF-IDF), scaling, feature selection,
clustering, and dimensionality reduction (SVD) of the scATAC-seq data was performed using Seurat (v4.0.5)75. Batch correction was performed using Harmony
(v0.1.0)76. Single-cell entropies were calculated using BioQC (v1.18.0)77,78.

8.

9.
10.
11.
12.
13.

14.
15.

16.

17.
18.
19.
20.

21.

22.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The raw RNA sequencing data generated in this study have been deposited in the Gene
Expression Omnibus (GEO) database under accession code GSE159543. The raw ChIP,
DIP, and ATAC sequencing data generated in this study have been deposited in the GEO
database under accession code GSE159886. The publicly available transcription factor
ChIP sequencing data used in this study are available in the ReMap 2020 database
[https://remap2020.univ-amu.fr]. The publicly available data on candidate cis-regulatory
elements used in this study are available through the ENCODE database [https://
www.encodeproject.org], the GeneHancer tracks in the UCSC Genome Browser [https://
genome.ucsc.edu], and the Hacer database [http://bioinfo.vanderbilt.edu/AE/HACER/].
Source data are provided with this paper for Fig. 1d and Fig. 6b-d. The remaining data
are available within the Article, Supplementary Information, or Source Data ﬁles. Source
data are provided with this paper.
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